Welcome to Chemren.com!Help Center 中文 Sign upLogin
Post Information
Products Suppliers Technologies Group Buying Surplus
Organic Raw Materials
Hydrocarbon Compounds Alcohols、Phenols、Ethers Aldehydes、Ketones、Quinones Esters Carboxylic Acids Halides Aromatic Compounds Heterocyclic Compounds Amino Acids、Proteins、Nucleic Acids Nitrogenous Organic Compounds Nitrogenous Organic Compounds Phosphorated Organic Compounds Sulfurated Organic Compounds Other Elemental Organic Compounds Organic Salts Carbohydrates Others
Organic Intermediates
Synthetic Intermediates Other Intermediates
Biochemicals and Pharmaceutical Chemicals
APIs Pharmaceutical Intermediates Biological Products Pharmaceutical Excipients Veterinary Drugs Finished Dosage Forms Pharmaceutical Impurities
Pesticides Fertilizers Pesticide Intermediates Others
Food and Feed Additives
Food Additives Feed Additives
Flavors and Fragrances
Flavors and Essences Spices Flavor and Fragrance Intermediates
Dyes and Pigments
Dyes Pigments Dye Intermediates
Catalysts and Additives
Additives and Auxiliaries Catalysts
Coatings and Paints
Coatings Paints Inks Others
Organic Adhesives Inorganic Adhesives
Inorganic Chemicals
Inorganic Salts Inorganic Acids Inorganic Alkalines Inorganic Oxides Elements Halides Others
Natural Products and Extracts
Plant Extracts Herbal Extracts Natural Products
Material Chemicals
Polymer Materials Metal and Ceramic Materials Nanomaterials
Electronic Chemicals
OFET Materials Electrode Materials Liquid Crystals
Household Chemicals
Cosmetics Oral Care Chemicals Skin Care Chemicals Household Insecticides Detergent Chemicals
Heat Exchange Equipment Reaction Equipment Crushing Equipment Mixing Equipment Separation Equipment Pressure Vessel Refrigeration Equipment Mass Transfer Equipment Molding Equipment Storage/Transport Equipment Drying Equipment Green Facilities Pump/Valve Equipment Conveying Equipment Instrumentation Auxiliary Equipment Crystallization Equipment Seal Machinery Heating Equipment Other Chemical Equipment
Other Chemicals
Other Chemicals
Location:Home > News Detail

Deerfield ponies up $100M for translational research deal with Harvard

Last Update:2019-03-14   |   Comments:0 A+ A-

Brief:Deerfield Management and Harvard University are teaming up on translational R&D to speed up the route to the clinic for new therapies discovered at Harvard. The duo is setting up a new company dubbed Lab1636, with $100 million in backing from Deerfield.

 Harvard Medical School
Lab1636 will support Harvard R&D projects at various stages of drug discovery and development. (timsackton/CC BY-SA 2.0)

Deerfield Management and Harvard University are teaming up on translational R&D to speed up the route to the clinic for new therapies discovered at Harvard. The duo is setting up a new company dubbed Lab1636, with $100 million in backing from Deerfield. 


“By working with an alliance partner who is prepared to support early-stage research and to invest in the success of pre-clinical and clinical-stage commercial development, we’re enhancing the opportunities for Harvard’s life-changing innovations to reach patients in need,” said Isaac Kohlberg, senior associate provost and chief technology development officer at Harvard, in a statement. 


The new company will be wholly owned by Deerfield’s affiliates and will support Harvard R&D projects at various stages of drug discovery and development. Lab1636 could help teams from Harvard validate targets or reach the proof of concept needed to file an IND application. In addition to funding research on campus, Lab1636 may also help Harvard researchers license their work out to other companies when it “eventually outgrows the lab bench,” Deerfield said in the statement. 


RELATED: Deerfield sets up $80M to pursue protein degradation R&D at new Dana-Farber center 

“The sheer scope of this collaboration with Deerfield may prove transformative for Harvard research,” said Vivian Berlin, managing director of strategic partnerships in Harvard’s Office of Technology Development. “This alliance has immense potential to bridge the development gap, ensure continuity of resources, and complement our other major translational programs, such as the Blavatnik Biomedical Accelerator.”  


As for which R&D projects will get funding from Lab1636—these will be selected by a joint advisory committee. They will focus on developing new therapeutics and, “ideally,” many will advance to IND application and clinical trials. 


“Harvard is an outstanding partner for an alliance,” said James Flynn, managing partner at Deerfield. “The University’s outstanding science, breadth of technologies, and mix of esteemed junior and senior faculty constitute a fertile environment for the continuous generation of novel insights. This, in combination with its experience advancing potential therapeutics, makes it the perfect place to establish an impactful translational partnership.” 




About Us
Contact Us
User Agreement
Privacy Policy
Resource Docking
Offline Activities
Technical Services
Sales Promotion
Update Info
Retrieve Password
Sign Up
User Center
Product Presales
Technology Purchase
Technology Transfer
Sell Products